NCT06613373View on ClinicalTrials.gov

An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2026

Conditions
Breast Cancer
Interventions
DRUG

Dalpiciclib

Dalpiciclib: 150 mg (p.o.) was given once daily for 3 weeks, followed by 1 week off in each 4-week cycle.

All Listed Sponsors
lead

Jiangsu Famous Medical Technology Co., Ltd.

INDUSTRY

NCT06613373 - An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer | Biotech Hunter | Biotech Hunter